What Is KPV?

KPV is a tripeptide (Lys-Pro-Val) corresponding to the three C-terminal amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino-acid peptide produced by the pituitary and skin cells with broad anti-inflammatory effects. Researchers identified KPV as retaining much of alpha-MSH's anti-inflammatory activity in a far smaller package (three amino acids rather than thirteen), which made it more tractable for pharmaceutical development and more resistant to degradation.

Alpha-MSH itself has a documented history in anti-inflammatory research across skin, gut, and central nervous system contexts. Catania and colleagues at the University of Milan and Luger's group in Germany spent decades characterizing its pharmacology. KPV sits within that body of work as the minimal functional fragment most associated with anti-inflammatory activity.

KPV is not approved by the FDA or any equivalent regulatory body. It is not a scheduled substance in the United States. It is sold as a research compound and, depending on the formulation, can be taken orally — an unusual characteristic among peptides, which are typically destroyed by digestive enzymes before reaching systemic circulation.

What Does the Research Say?

Evidence level: Preliminary — KPV has consistent mechanistic and animal data, primarily from IBD models, with a plausible oral delivery rationale for gut-targeted effects. Human data is extremely limited. The anti-inflammatory mechanism is well-characterized in the parent compound (alpha-MSH); translation to KPV specifically is supported in animal work but not confirmed in clinical trials.

Mechanism

KPV acts primarily through melanocortin receptors, particularly MC1R and MC3R. Activation of these receptors suppresses NF-κB signaling, a central regulator of inflammatory gene expression. Downstream, this reduces production of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta. This is the same basic pathway through which alpha-MSH exerts its anti-inflammatory effects; KPV retains this activity at a smaller molecular scale.

Antimicrobial activity is a secondary mechanism. Alpha-MSH-derived peptides have direct antimicrobial properties against certain bacteria and fungi through membrane disruption, and KPV shares this property to some degree. This is one reason it has been studied in the context of infected wounds and gut dysbiosis, not just pure inflammation.

The oral delivery story is mechanistically interesting. Most peptides are degraded by stomach acid and digestive enzymes before they reach therapeutic concentrations in the bloodstream. KPV's small size and structure allow it to survive gastrointestinal conditions better than most peptides, and for gut-targeted indications like IBD, systemic absorption may not even be required — local activity in the intestinal mucosa is the relevant mechanism.

Animal Studies

The most developed animal evidence base is for IBD. Colitis models in mice, using agents like TNBS (trinitrobenzenesulfonic acid) and DSS (dextran sulfate sodium) to induce intestinal inflammation, have consistently shown that KPV treatment reduces inflammatory markers, tissue damage, and disease activity scores. Kannengiesser et al. documented KPV's anti-inflammatory potential in multiple murine colitis models, including oral administration, which is relevant because oral delivery could eventually translate to non-invasive treatment.

Wound healing and skin inflammation studies in animals show KPV reducing inflammatory responses at injury sites. The skin anti-inflammatory data aligns with the broader alpha-MSH literature on cutaneous inflammation.

Human Studies

Human data for KPV is extremely limited. There are no published clinical trials of KPV for IBD or any other indication. The human evidence is confined to cell culture work with human cell lines and extrapolation from the alpha-MSH clinical literature, which has more human data.

The mechanistic rationale is strong enough that some researchers view KPV as a candidate for IBD drug development — the anti-inflammatory pathway is real, the oral delivery case is plausible, and the existing drugs for IBD (biologics, corticosteroids, aminosalicylates) have significant side effect profiles that create room for alternatives. None of that translates to evidence that KPV works in human IBD until trials are conducted.

Community and Anecdotal Reports

KPV has a smaller community following than most peptides on this site. It is most commonly discussed in the context of IBD, leaky gut, and gut inflammation — users who have exhausted conventional options or who want to try something alongside their prescribed treatments. Reports describe reduced gut symptoms, improved stool consistency, and reduced pain in people with active IBD symptoms.

These reports are deeply confounded. IBD has significant natural variation, placebo effects are large, and most people reporting improvement are also doing other things simultaneously. They are worth noting as consistent with the mechanism; they are not clinical evidence.

Common Uses

Inflammatory Bowel Disease

The most evidence-backed application, relative to what exists. KPV has the most animal data here, the oral delivery case is specific to this indication, and the mechanistic pathway is well-characterized. Human trials do not exist. People taking KPV for IBD are extrapolating from colitis models.

Gut Inflammation and Leaky Gut

Community users frequently take KPV for general gut inflammation, dysbiosis, and what is often described as "leaky gut" — increased intestinal permeability. The anti-inflammatory mechanism could theoretically address intestinal lining inflammation. Whether it meaningfully affects intestinal permeability specifically has not been studied.

Wound Healing and Skin Inflammation

Animal studies and the alpha-MSH literature support anti-inflammatory and antimicrobial activity in skin contexts. Some users apply KPV topically for wound healing and skin inflammation. The evidence base here is thinner than for gut applications.

Systemic Anti-Inflammatory

Users with systemic inflammatory conditions (autoimmune diseases, joint inflammation) sometimes try KPV for its anti-inflammatory properties. The mechanism would apply systemically with injectable use, but no clinical evidence for systemic anti-inflammatory effects in humans exists.

Delivery Methods

Oral

Oral delivery is viable for KPV in a way that is not typical for most peptides. Because the gut is both a target tissue and a delivery route, oral KPV can produce local anti-inflammatory effects in the intestinal mucosa without requiring systemic absorption. Some community users take oral KPV capsules specifically for this reason. Published pharmacokinetic data for oral KPV absorption in humans is not available.

Subcutaneous Injection

Subcutaneous injection is used for systemic delivery in biohacking contexts. This route ensures systemic bioavailability, though for gut-specific indications it is not clear that systemic delivery is preferable to oral. Injection carries standard risks: infection risk with lapses in sterile technique, injection site reactions, and the complexity of handling reconstituted peptides.

PEPVi does not provide dosing guidance. Dosing decisions should be made in consultation with a qualified healthcare provider.

Safety and Side Effects

KPV has a favorable safety signal in animal studies — it is well-tolerated in the IBD models and anti-inflammatory applications. No human safety trials exist, so there is no clinical safety data to report.

The melanocortin pathway has skin pigmentation effects, which is where alpha-MSH takes its name. KPV at typical research doses is generally not considered to produce significant pigmentation changes, but the theoretical concern exists with any melanocortin agonist.

Interactions with prescribed anti-inflammatory medications (corticosteroids, biologics, aminosalicylates) have not been studied. People taking immunosuppressive or anti-inflammatory medications for IBD or other conditions should discuss KPV with their physician before adding it.

Long-term human safety data does not exist. That is the accurate baseline for KPV.

KPV is not FDA-approved for any indication. It is not a scheduled controlled substance under DEA regulations. It is sold as a research compound.

KPV is one of the 12 peptides targeted in the current reclassification process. For details on what changes in July 2026, see What RFK's Peptide Reclassification Means for You.

Frequently Asked Questions

KPV's small size (three amino acids) makes it more resistant to gastrointestinal degradation than larger peptides. Most peptides are broken down by stomach acid and proteases before reaching meaningful systemic concentrations. KPV survives this process well enough to exert local effects in the intestinal mucosa, which is relevant for gut-targeted indications. Whether it achieves meaningful systemic absorption orally has not been established in humans.

Animal models say the anti-inflammatory mechanism is active in colitis contexts. Human clinical trials have not been conducted. People taking KPV for IBD are using the animal evidence and community reports as their basis, not human trial data. The mechanism is solid; the clinical evidence is absent.

BPC-157 works primarily through growth factor pathways (EGF receptor, NO system) and has extensive gut healing data. KPV works through the melanocortin receptor pathway with NF-κB suppression. Different mechanisms, some overlapping applications. BPC-157 has more animal evidence across more tissues; KPV has a more specific anti-inflammatory mechanism. Some users take both. There is no studied combination protocol.

Animal safety data is favorable. Human safety data does not exist. The melanocortin receptor pathway raises theoretical pigmentation concerns with extended use, though this has not been documented in practice. Anyone on prescribed anti-inflammatory or immunosuppressive medications should discuss KPV with their physician before use.

Learn More

Sources

  1. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. "Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases." Endocrine Reviews, 2008. — Comprehensive review of alpha-MSH and derivative peptides including KPV; covers mechanisms, anti-inflammatory evidence, and therapeutic potential.

  2. Kannengiesser K, Maaser C, Heidemann J, et al. "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease." Inflammatory Bowel Diseases, 2008. — Primary animal evidence for KPV in colitis models; demonstrates anti-inflammatory activity including with oral delivery.

  3. Catania A. "Neuroprotective actions of melanocortins: a therapeutic opportunity." Trends in Neurosciences, 2008. — Review of melanocortin anti-inflammatory signaling and neuroprotective mechanisms; provides mechanistic context for how alpha-MSH-derived peptides including KPV modulate inflammatory pathways.